Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride

Pharmacopsychiatry

Volumn 42, Issue 6, 2009, Pages 277-283

  Lambert, M ^a,d   Schimmelmann, B G ^b,d   Naber, D ^a   Eich, F X ^c   Schulz, H ^a   Huber, C G ^a   Karow, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d University Hospital Hamburg Eppendorf ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SCALE OF OCCUPATIONAL AND FUNCTIONAL ASSESSMENT; SCHIZOPHRENIA; SOCIAL INTERACTION; SUBJECTIVE WELLBEING UNDER NEUROLEPTIC SCALE; TREATMENT OUTCOME; TREATMENT RESPONSE; WELLBEING;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; LINEAR MODELS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SULPIRIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70450260607     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1234105     Document Type: Article

References (42)

1. Leucht S, Busch R, Kissling W. Early prediction of antipsychotic nonresponse among patients with schizophrenia. The Journal of clinical psychiatry 2007; 68: 352-360 (Pubitemid 46506798)
2. Lambert M, Schimmelmann BG, Naber D et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. The Journal of clinical psychiatry 2006; 67: 1690-1697 (Pubitemid 44955148)
3. Lambert M, Naber D, Eich FX et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta psychiatrica Scandinavica 2007; 115: 106-113 (Pubitemid 46114871)
4. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. The American journal of psychiatry 2004; 161: 1-56
5. Agid O, Kapur S, Arenovich T et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of general psychiatry 2003; 60: 1228-1235 (Pubitemid 37494076)
6. Correll CU, Malhotra AK, Kaushik S et al. Early prediction of antipsychotic response in schizophrenia. The American journal of psychiatry 2003; 160: 2063-2065 (Pubitemid 39619650)
7. Chang YC, Lane HY, Yang KH et al. Optimizing early prediction for antipsychotic response in schizophrenia. Journal of clinical psychopharmacology 2006; 26: 554-559 (Pubitemid 44772730)
8. Leucht S, Busch R, Hamann J et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confi rmed and extended. Biological psychiatry 2005; 57: 1543-1549 (Pubitemid 40805384)
9. Li M, Fletcher PJ, Kapur S. Time course of the antipsychotic eff ect and the underlying behavioral mechanisms. Neuropsychopharmacology 2007; 32: 263-272 (Pubitemid 46106933)
10. Agid O, Seeman P, Kapur S. The " delayed onset " of antipsychotic action-an idea whose time has come and gone. J Psychiatry Neurosci 2006; 31: 93-100
11. Flyckt L, Mattsson M, Edman G et al. Predicting 5-year outcome in fi rst-episode psychosis: construction of a prognostic rating scale. The Journal of clinical psychiatry 2006; 67: 916-924 (Pubitemid 44049090)
12. Hofer A, Rettenbacher MA, Edlinger M et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry 2007; 40: 1-8 (Pubitemid 46568353)
13. Andreasen NC, Carpenter Jr WT, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449 (Pubitemid 40343909)
14. Lambert M, Schimmelmann BG, Karow A et al. Subjective well-being and initial dysphoric reaction under antipsychotic drugs-concepts, measurement and clinical relevance. Pharmacopsychiatry 2003; 36 Suppl 3: S181-S190 (Pubitemid 38085135)
15. DeHaan L, Weisfelt M, Dingemans PM et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Defi cit Syndrome Scale [Medico-economic study of Leponex (clozapine) in the Bordeaux Charles Perrens Hospital Center]. Psychopharmacology (Berl) 2002; 162: 24-28
16. Schimmelmann BG, Paulus S, Schacht M et al. Subjective distress related to side eff ects and subjective well-being in fi rst admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005; 15: 249-258 (Pubitemid 40734104)
17. Putzhammer A, Perfahl M, Pfeiff L et al. Correlation of subjective wellbeing in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 2005; 38: 132-138 (Pubitemid 40965967)
18. Karow A, Czekalla J, Dittmann RW et al. Association of subjective wellbeing, symptoms, and side eff ects with compliance after 12 months of treatment in schizophrenia. The Journal of clinical psychiatry 2007; 68: 75-80 (Pubitemid 46220127)
19. Wehmeier PM, Kluge M, Schacht A et al. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophrenia research 2007; 91: 178-186 (Pubitemid 46320898)
20. Wehmeier PM, Kluge M, Schneider E et al. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry 2007; 31: 703-712 (Pubitemid 46467049)
21. WHO. The ICD-10 classifi cation of mental and behavioural disorders. Diagnostic criteria for research. In. Geneva: WHO; 1993
22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. SchizophrBull 1987; 13: 261-276 (Pubitemid 18039085)
23. Guy W. Clinical Global Impression In: Guy W, ed ECDEU Assessment Manual for Psychopharmacology, rev. Rockville. US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch. Division of Extramural Research Programms; 1976: pp. 218-222
24. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington. DC: American Psychiatric Press; 1994
25. Naber D, Moritz S, Lambert M et al. Improvement of chizophrenic patients; subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50 (1- 2): 79-88 (Pubitemid 32510889)
26. Haro JM, Kamath SA, Ochoa S et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; 16-23 (Pubitemid 36683637)
27. Naber D. A self-rating to measure subjective eff ects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 Suppl 3: 133-138 (Pubitemid 26054887)
28. Lambert M, Conus P, Schimmelmann BG et al. Comparison of olanzapine and risperidone in 367 fi rst-episode patients with non-aff ective or aff ective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 2005; 38: 206-213 (Pubitemid 41414866)
29. Haro JM, Edgell ET, Novick D et al. Eff ectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111: 220-231 (Pubitemid 40342191)
30. Kopelowicz A, Liberman RP. Biobehavioral treatment and rehabilitation of schizophrenia. Harv Rev Psychiatry 1995; 3: 55-64
31. Haro JM, Novick D, Suarez D et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. Journal of clinical psychopharmacology 2006; 26: 571-578 (Pubitemid 44772733)
32. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. Psychiatric services. Washington, DC; 2005; 56: 735-742
33. Aiken LR. Formulas for equating ratings on diff erent scales. Educational and Psychological Measurement 1987; 51-54
34. Perkins DO, Gu H, Boteva K et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-1804 (Pubitemid 41428609)
35. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R et al. Predictors of acute treatment response in patients with a fi rst episode of non-aff ective psychosis: sociodemographics, premorbid and clinical variables. Journal of psychiatric research 2007; 41: 659-666 (Pubitemid 46509645)
36. McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry research 1991; 37: 97-103
37. Davis JM, Chen N, Glick ID. A meta-analysis of the effi cacy of secondgeneration antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564
38. Semiz UB, Cetin M, Basoglu C et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatmentresistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry 2007; 31: 1330-1336 (Pubitemid 47081323)
39. Remington G, Saha A, Chong SA et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS drugs 2005; 19: 843-872
40. de Haan L, Nimwegen L, Amelsvoort T et al. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of fi rst episode schizophrenia. Pharmacopsychiatry 2008; 41: 125-128
41. Jager M, Messer T, Laux G et al. Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures. Pharmacopsychiatry 2008; 41: 190-195
42. Wiersma D, Wanderling J, Dragomirecka E et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centers. Psychological medicine 2000; 30: 1155-1167